A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.

Trial Profile

A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2016 Results (n=14) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top